The DOI matches its Crossref record.
Clusterin (apoJ) Alters the Aggregation of Amyloid β-Peptide (Aβ1-42) and Forms Slowly Sedimenting Aβ Complexes That Cause Oxidative Stress
Abstract
Clusterin (apoJ), a multifunctional apolipoprotein made by cells in the brain and many other locations, is associated with aggregated amyloid beta-peptide (A beta) in senile and diffuse plaques of Alzheimer's disease (AD). We observed that purified human serum clusterin partially blocked the aggregation of synthetic A beta 1-42, as shown by centrifugal assays (14,000g x 10 min) and by atomic force (scanning probe) microscopy. Slowly sedimenting A beta complexes were formed in the presence of clusterin, which included aggregates > 200 kDa that resist dissociation by low concentrations of SDS. Clusterin enhanced the oxidative stress caused by A beta, as assayed by oxidative stress in PC12 cells with MTT, which is widely used to estimate neurotoxicity. These indications of enhanced neurotoxicity by the MTT assay were observed in the highly aggregated rapidly sedimenting fraction, but also in more slowly sedimenting "soluble" forms. This novel activity of slowly sedimenting A beta may enhance the neurotoxicity of A beta deposits in AD brains, because soluble complexes have a potential for diffusing to damage distal neurons.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“oligomeric Aβ rather than fibril Aβ is regarded as the toxic species of this peptide [143,144,145,146].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [143]
In the citing paper
“Furthermore, APOE and CLU have been shown to cooperate in suppressing Aβ deposition 33 and APOE and CLU may critically modify Aβ clearance at the blood brain barrier”
From Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease (2009) · cites this paper as [33]
In the citing paper
“A 1-42 aged according to this protocol is a mixture of fibrils and soluble globular aggregates, and is active to astrocytes (37,38) and toxic to neurons (26,27).”
From Apolipoprotein E Receptors Mediate the Effects of β-Amyloid on Astrocyte Cultures (2000) · cites this paper as [26]
In the citing paper
“In vitro, apoE and apoJ form stable complexes with A (11, 16 -20), alter the aggregation of various A peptides (21)(22)(23), and affect A neurotoxicity (24 -27).”
From Apolipoprotein E Receptors Mediate the Effects of β-Amyloid on Astrocyte Cultures (2000) · cites this paper as [26]
In the citing paper
“ApoJ has been shown to potentiate the formation of a neurotoxic species of A (26,27).”
From Apolipoprotein E Receptors Mediate the Effects of β-Amyloid on Astrocyte Cultures (2000) · cites this paper as [26]
In the citing paper
“ApoE, apoJ, and most recently ␣ 2 -macroglobulin have been shown to form a complex with A that may facilitate clearance of the peptide (25-27, 50, 51).”
From Apolipoprotein E Receptors Mediate the Effects of β-Amyloid on Astrocyte Cultures (2000) · cites this paper as [26]
In the citing paper
“CLU levels also appear to affect aggregation of Aβ (Oda, et al., 1995,Wilson, et al., 2008)”
From A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin (2016) · cites this paper as Oda, et al., 1995
Citations
Cites
Still being checked.
Cited by
Sorted by citations
Items 101–200 of 350
Disease modifying therapy for AD?1
Golde, T. E. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04211.x · Cited by 117
Brain site-specific proteome changes in aging-related dementia
Manavalan, A., Mishra, M., Feng, L., Sze, S. K., Akatsu, H., & Heese, K. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.76 · Cited by 115
LaDu, M. J., Shah, J. A., Reardon, C. A., Getz, G. S., Bu, G., Hu, J., Guo, L., & Van Eldik, L. J. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(01)00050-x · Cited by 118
Pasinetti, G. M. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00113-3 · Cited by 115
Self-citationFukuyama, R., Mizuno, T., Mizuno, T., Mori, S., Nakajima, K., Fushiki, S., & Yanagisawa, K. (2000) · European Neurology · doi:10.1159/000008156 · Cited by 113
ADDLs and the signaling web that leads to Alzheimer’s disease
Krafft, G. A., & Klein, W. L. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.07.012 · Cited by 113
Self-citationThe Essential Role of Soluble Aβ Oligomers in Alzheimer’s Disease
Wang, Z.-X., Tan, L., Liu, J., & Yu, J.-T. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9143-0 · Cited by 110
Synaptic targeting by Aβ oligomers (ADDLS) as a basis for memory loss in early Alzheimer's disease
Klein, W. L. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2005.11.003 · Cited by 109
Rukhsana Sultana, A., & Butterfield, D. A. (2009) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-009-9241-7 · Cited by 110
Redox proteomics and amyloid β-peptide: Insights into Alzheimer disease
Butterfield, D. A., & Boyd‐Kimball, D. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14589 · Cited by 105
Nilselid, A.-M., Davidsson, P., Nägga, K., Andreasen, N., Fredman, P., & Blennow, K. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2005.12.005 · Cited by 104
Apolipoprotein E Receptors Mediate the Effects of β-Amyloid on Astrocyte Cultures
LaDu, M. J., Shah, J. A., Reardon, C. A., Getz, G. S., Bu, G., Hu, J., Guo, L., & Van Eldik, L. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000602200 · Cited by 103
Hu, J., & Eldik, L. J. V. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01804-1 · Cited by 101
The Blood–Brain Barrier in Alzheimer's Disease
Sharma, H. S., Castellani, R. J., Smith, M. A., & Sharma, A. (2012) · International review of neurobiology · doi:10.1016/b978-0-12-386986-9.00003-x · Cited by 105
Bcl-2 Facilitates Recovery from DNA Damage after Oxidative Stress
Deng, G., Su, J. H., Ivins, K. J., Houten, B. V., & Cotman, C. W. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7145 · Cited by 99
Cerf, E., Gustot, A., Goormaghtigh, E., Ruysschaert, J.-M., & Raussens, V. (2011) · The FASEB Journal · doi:10.1096/fj.10-175976 · Cited by 92
Biphasic Effects of Insulin on Islet Amyloid Polypeptide Membrane Disruption
Brender, J., Lee, E. L., Hartman, K. L., Wong, P. T., Ramamoorthy, A., Steel, D. G., & Gafni, A. (2011) · Biophysical Journal · doi:10.1016/j.bpj.2010.09.070 · Cited by 93
ApoE and Aβ1–42 Interactions: Effects of Isoform and Conformation on Structure and Function
Manelli, A. M., Stine, W. B., Van Eldik, L. J., & LaDu, M. J. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:3:235 · Cited by 95
Self-citationZameer, A., Kasturirangan, S., Emadi, S., Nimmagadda, S. V., & Sierks, M. R. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.09.068 · Cited by 96
The CLU-files: disentanglement of a mystery
Rohne, P., Prochnow, H., & Koch-Brandt, C. (2015) · BioMolecular Concepts · doi:10.1515/bmc-2015-0026 · Cited by 96
Tew, D. J., Bottomley, S. P., Smith, D. P., Ciccotosto, G. D., Babon, J., Hinds, M. G., Masters, C. L., Cappai, R., & Barnham, K. J. (2008) · Biophysical Journal · doi:10.1529/biophysj.107.119909 · Cited by 93
Kański, J., Aksenova, M. V., Schöneich, C., & Butterfield, D. A. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00821-3 · Cited by 93
Barone, E., Cenini, G., Domenico, F. D., Martin, S. K., Rukhsana Sultana, A., Mancuso, C., Murphy, M. P., Head, E., & Butterfield, D. A. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.12.007 · Cited by 93
Giannakopoulos, P., Kövari, E., French, L. E., Viard, I., Hof, P. R., & Bouras, C. (1998) · Acta Neuropathologica · doi:10.1007/s004010050815 · Cited by 90
Low‐n oligomers as therapeutic targets of Alzheimer’s disease
Ono, K., & Yamada, M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07187.x · Cited by 76
Apolipoprotein E and Alzheimer's disease: the protective effects of ApoE2 and E3
Rebeck, G. W., Kindy, M., & LaDu, M. J. (2002) · Journal of Alzheimer's Disease · doi:10.3233/jad-2002-4304 · Cited by 89
Clusterin and Alzheimer’s Disease
Calero, M., Rostagno, A. A., Frangione, B., & Ghiso, J. A. (2006) · Springer eBooks · doi:10.1007/0-387-23226-5_14 · Cited by 89
Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease
Butterfield, D. A., & Boyd-Kimball, D. (2020) · Antioxidants · doi:10.3390/antiox9090818 · Cited by 85
Eikelenboom, P., Veerhuis, R., van Exel, E. R., Hoozemans, J. J. M., Rozemüller, A. J. M., & van Gool, W. A. (2011) · Current Alzheimer Research · doi:10.2174/156720511795256080 · Cited by 87
Rahimi, F., Shanmugam, A., & Bitan, G. (2008) · Current Alzheimer Research · doi:10.2174/156720508784533358 · Cited by 88
Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation
Nilsson, L. N. G., Arendash, G. W., Leighty, R. E., Costa, D. A., Low, M. A., Garcia, M. F., Cracciolo, J. R., Rojiani, A. M., Wu, X., Bales, K. R., et al. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.12.011 · Cited by 88
Amino Acid Position-specific Contributions to Amyloid β-Protein Oligomerization
Maji, S. K., Loo, R. R. O., Inayathullah, M., Spring, S. M., Vollers, S. S., Condron, M. M., Bitan, G., Loo, J. A., & Teplow, D. B. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.038133 · Cited by 86
Transgenic C. elegans as a Model in Alzheimers Research
Wu, Y., & Luo, Y. (2005) · Current Alzheimer Research · doi:10.2174/1567205052772768 · Cited by 88
Saura, J., Petegnief, V., Wu, X., Liang, Y., & Paul, S. M. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01788.x · Cited by 84
Kański, J., Varadarajan, S., Aksenova, M. V., & Butterfield, D. A. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(01)00097-7 · Cited by 83
Clusterin levels are increased in A lzheimer's disease and influence the regional distribution of Aβ
Miners, J. S., Clarke, P., & Love, S. (2016) · Brain Pathology · doi:10.1111/bpa.12392 · Cited by 83
Kida, E., Choi-Miura, N.-H., & Wisniewski, K. E. (1995) · Brain Research · doi:10.1016/0006-8993(95)00482-6 · Cited by 79
Chun, J. T., Wang, L., Pasinetti, G. M., Finch, C. E., & Zlokovic, B. V. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7052 · Cited by 67
Self-citationADDLs & protofibrils —the missing links?
Klein, W. L. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00312-8 · Cited by 77
Poling, A. D., Morgan-Paisley, K., Panos, J., Kim, E., O‘Hare, E., Cleary, J. P., Lesné, S., Ashe, K. H., Porritt, M., & Baker, L. E. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.06.001 · Cited by 77
High Density Lipoprotein Inhibits Assembly of Amyloid β-Peptides into Fibrils
Olesen, O. F., & Dagø, L. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2372 · Cited by 76
Clusterin in the male reproductive system: localization and possible function
Bailey, R. W., & Griswold, M. D. (1999) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(99)00016-7 · Cited by 75
Commentary: is Alzheimer's disease uniquely human?
Finch, C. E., & Austad, S. N. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.10.025 · Cited by 72
Self-citationPark, H.-H., Lee, K.-Y., Kim, S., Lee, J. W., Choi, N.-Y., Lee, E.-H., Lee, Y. J., Lee, S.-H., & Koh, S.-H. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.12.015 · Cited by 72
Rukhsana Sultana, A., Marzia Perluigi, A., & Butterfield, D. A. (2005) · Journal of Chromatography B · doi:10.1016/j.jchromb.2005.09.024 · Cited by 72
Wyatt, A. R., Yerbury, J. J., Poon, S., Dabbs, R. A., & Wilson, M. R. (2009) · Advances in cancer research · doi:10.1016/s0065-230x(09)04006-8 · Cited by 70
Developmental origins of aging in brain and blood vessels: an overview
Finch, C. E. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.03.015 · Cited by 69
Self-citationExtracellular chaperones prevent Aβ42-induced toxicity in rat brains
Cascella, R., Conti, S., Tatini, F., Evangelisti, E., Scartabelli, T., Casamenti, F., Wilson, M. R., Chiti, F., & Cecchi, C. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.04.012 · Cited by 70
Roles of Extracellular Chaperones in Amyloidosis
Wyatt, A. R., Yerbury, J. J., Dabbs, R. A., & Wilson, M. R. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.01.004 · Cited by 67
A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin
Deming, Y., Xia, J., Cai, Y., Lord, J., Holmans, P., Bertelsen, S., Holtzman, D., Morris, J. C., Bales, K., Pickering, E. H., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.09.009 · Cited by 66
“CLU levels also appear to affect aggregation of Ab (Oda et al., 1995; Wilson et al., 2008).”
Conformational Dynamics of Amyloid β-Protein Assembly Probed Using Intrinsic Fluorescence
Maji, S. K., Amsden, J. J., Rothschild, K. J., Condron, M. M., & Teplow, D. B. (2005) · Biochemistry · doi:10.1021/bi0508284 · Cited by 66
Clusterin in Alzheimer's disease
Wu, Z., Yu, J., Li, Y., & Tan, L. (2012) · Advances in clinical chemistry · doi:10.1016/b978-0-12-394317-0.00011-x · Cited by 63
Palavicini, J. P., Wang, C., Chen, L., HoSang, K. M., Wang, J., Tomiyama, T., Mori, H., & Han, X. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0460-6 · Cited by 62
Zatta, P. F., Tognon, G., & Carampin, P. (2003) · Journal of Pineal Research · doi:10.1034/j.1600-079x.2003.00058.x · Cited by 64
Formation of highly toxic soluble amyloid beta oligomers by the molecular chaperone prefoldin
Sakono, M., Zako, T., Ueda, H., Yohda, M., & Maeda, M. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06727.x · Cited by 64
Apolipoprotein E Attenuates β‐Amyloid‐Induced Astrocyte Activation
Hu, J., LaDu, M. J., & Van Eldik, L. J. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71041626.x · Cited by 52
Laminin inhibits amyloid-β-peptide fibrillation
Bronfman, F. C., Garrido, J., Alvarez, A. R., Morgan, C., & Inestrosa, N. C. (1996) · Neuroscience Letters · doi:10.1016/s0304-3940(96)13147-5 · Cited by 62
Sörgjerd, K. M., Zako, T., Sakono, M., Stirling, P. C., Leroux, M. R., Saito, T., Nilsson, P., Sekimoto, M., Saido, T. C., & Maeda, M. (2013) · Biochemistry · doi:10.1021/bi301705c · Cited by 61
Chapter 9 Oxidative Stress in Malignant Progression
Trougakos, I. P., & Gonos, E. S. (2009) · Advances in cancer research · doi:10.1016/s0065-230x(09)04009-3 · Cited by 60
Clusterin contributes to early stage of Alzheimer's disease pathogenesis
Oh, S., Kim, M. S., Park, S., Son, H., Kim, S., Kim, M., Jo, D., Tak, E., & Lee, J. (2018) · Brain Pathology · doi:10.1111/bpa.12660 · Cited by 59
Chennakesavan, K., Saravanan, N., Essa, M. M., Guillemin, G. J., Jayachandran, S. K., & Anusuyadevi, M. (2018) · Neurological Research · doi:10.1080/01616412.2018.1544745 · Cited by 58
Suppression of apolipoprotein C‐II amyloid formation by the extracellular chaperone, clusterin
Hatters, D. M., Wilson, M. R., Easterbrook‐Smith, S. B., & Howlett, G. J. (2002) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2002.02957.x · Cited by 58
Toxicity mediated by soluble oligomers of β‐amyloid(1–42) on cholinergic SN56.B5.G4 cells
Heinitz, K., Beck, M., Schliebs, R., & Perez-Polo, J. R. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04015.x · Cited by 58
Traumatic brain injury induces biphasic upregulation of ApoE and ApoJ protein in rats
Iwata, A., Browne, K. D., Chen, X., Yuguchi, T., & Smith, D. H. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20607 · Cited by 53
β-Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease
Dumery, L., Bourdel, F., Soussan, Y., Fialkowsky, A., Viale, S., Nicolas, P., & Reboud‐Ravaux, M. (2001) · Pathologie Biologie · doi:10.1016/s0369-8114(00)00009-2 · Cited by 55
Dickerson, T. J., & Janda, K. D. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1332847100 · Cited by 55
Clusterin in Alzheimer’s disease: a player in the biological behavior of amyloid-beta
Li, X., Ma, Y., Xu, W., Li, Y., Wu, H., Zhuang, J., & Zhao, Z. (2013) · Neuroscience Bulletin · doi:10.1007/s12264-013-1391-2 · Cited by 56
Increased Clusterin Expression in Fuchs’ Endothelial Dystrophy
Jurkunas, U. V., Bitar, M. S., Rawe, I., Harris, D. L., Colby, K. A., & Joyce, N. C. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-1405 · Cited by 54
Monji, A., Utsumi, H., Ueda, T., Imoto, T., Yoshida, I., Hashioka, S., Tashiro, K., & Tashiro, N. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00392.x · Cited by 53
Apolipoprotein J (clusterin) activates rodent microglia in vivo and in vitro
Xie, Z., Harris‐White, M. E., Wals, P. A., Frautschy, S. A., Finch, C. E., & Morgan, T. E. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03065.x · Cited by 53
Self-citationClusterin ameliorates tau pathology in vivo by inhibiting fibril formation
Wojtas, A., Carlomagno, Y., Sens, J. P., Kang, S. S., Jensen, T. D., Kurti, A., Baker, K. E., Berry, T. J., Phillips, V. R., Castanedes, M. C., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01079-1 · Cited by 53
ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease
Krafft, G. A., Jerecı̀ć, J., Siemers, E., & Cline, E. N. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.848215 · Cited by 54
Self-citationShotgun Protein Profile of Human Adipose Tissue and Its Changes in Relation to Systemic Amyloidoses
Brambilla, F., Lavatelli, F., Silvestre, D. D., Valentini, V., Palladini, G. O., Merlini, G., & Mauri, P. (2013) · Journal of Proteome Research · doi:10.1021/pr400583h · Cited by 54
Relationship Between Multifunctional Protein "Clusterin" and Alzheimer Disease
Choi-Miura, N.-H., & Oda, T. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00106-6 · Cited by 54
Self-citationLish, A. M., Grogan, E. F. L., Benoit, C. R., Pearse, R. V., Heuer, S. E., Luquez, T., Orme, G. A., Galle, P. C., Milinkeviciute, G., Green, K. N., et al. (2025) · Neuron · doi:10.1016/j.neuron.2025.03.034 · Cited by 55
Carrano, A., Snkhchyan, H., Kooij, G., van der Pol, S., van Horssen, J., Veerhuis, R., Hoozemans, J., Rozemuller, A., & de Vries, H. E. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.09.015 · Cited by 51
Amyloid in Alzheimer's disease and prion-related encephalopathies: studies with synthetic peptides
Forloni, G., Tagliavini, F., Bugiani, O., & Salmona, M. (1996) · Progress in Neurobiology · doi:10.1016/0301-0082(96)00013-5 · Cited by 51
Pogocki, D. (2003) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2003-1463 · Cited by 50
Inflammation in Alzheimer’s Disease
Finch, C. E., Longo, V. D., Miyao, A., Morgan, T. E., Rozovsky, I., Soong, Y., Wei, M., Xie, Z., & Zanjani, H. (2001) · Humana Press eBooks · doi:10.1007/978-1-59259-006-3_4 · Cited by 50
Self-citationAlzheimer's disease genes and autophagy
Yoon, S.-Y., & Kim, D.-H. (2016) · Brain Research · doi:10.1016/j.brainres.2016.03.018 · Cited by 42
Wälti, M. A., Orts, J., Vögeli, B., Campioni, S., & Riek, R. (2015) · ChemBioChem · doi:10.1002/cbic.201402595 · Cited by 49
VLDL-specific increases of fatty acids in autism spectrum disorder correlate with social interaction
Usui, N., Iwata, K., Miyachi, T., Takagai, S., Wakusawa, K., Nara, T., Tsuchiya, K. J., Matsumoto, K., Kurita, D., Kameno, Y., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102917 · Cited by 45
Reversible Inactivation of Superoxide‐Sensitive Aconitase in Aβ1‐42‐Treated Neuronal Cell Lines
Longo, V. D., Viola, K. L., Klein, W. L., & Finch, C. E. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0751977.x · Cited by 46
Self-citationGenetic Alterations of the BRI2 gene: Familial British and Danish Dementias
J, G., A, R., Y, T., T, L., M, B.-M., H, B., G, P., J, H., R, L., T, R., et al. (2006) · Brain Pathology · doi:10.1111/j.1750-3639.2006.tb00563.x · Cited by 44
Bazrgar, M., Khodabakhsh, P., Prudencio, M., Mohagheghi, F., & Ahmadiani, A. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105805 · Cited by 45
A Reexamination of the Role of Clusterin as a Complement Regulator
Hochgrebe, T. T., Humphreys, D. T., Wilson, M. R., & Easterbrook‐Smith, S. B. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4459 · Cited by 44
Qi, X.-M., Wang, C., Chu, X., Li, G., & Ma, J. (2018) · BMC Neuroscience · doi:10.1186/s12868-018-0402-7 · Cited by 44
Aksenova, M. V., Aksenov, M. Y., Butterfield, D. A., & Carney, J. M. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12717-8 · Cited by 39
Gupta, V. B., Doecke, J. D., Hone, E., Pedrini, S., Laws, S. M., Thambisetty, M., Bush, A. I., Rowe, C. C., Villemagne, V. L., Ames, D. J., et al. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.12.001 · Cited by 39
Sex Hormone Decline and Amyloid β Synthesis, Transport and Clearance in the Brain
Duarte, A. C., Hrynchak, M. V., Gonçalves, I., Quintela, T., & Santos, C. R. A. (2016) · Journal of Neuroendocrinology · doi:10.1111/jne.12432 · Cited by 42
Laminin 1 Attenuates β‐Amyloid Peptide Aβ(1‐40) Neurotoxicity of Cultured Fetal Rat Cortical Neurons
Drouet, B., Pinçon‐Raymond, M., Chambaz, J., & Pillot, T. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0730742.x · Cited by 40
Molecular simulations of amyloid beta assemblies
Grasso, G., & Danani, A. (2020) · Advances in Physics X · doi:10.1080/23746149.2020.1770627 · Cited by 40
Rapid initiation of cell cycle reentry processes protects neurons from amyloid-β toxicity
Ippati, S., Deng, Y., van der Hoven, J., Heu, C., van Hummel, A., Chua, S. W., Parić, E., Chan, G., Feiten, A., Fath, T., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2011876118 · Cited by 39
Advances on the Understanding of the Origins of Synaptic Pathology in AD
Lacor, P. N. (2007) · Current Genomics · doi:10.2174/138920207783769530 · Cited by 40
In vitroOligomerization and Fibrillogenesis of Amyloid-beta Peptides
Benseny‐Cases, N., Klementieva, O., & Cladera, J. (2012) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-5416-4_3 · Cited by 39
Can Estrogens Prevent Neurodegeneration?
Schneider, L. S. S., & Finch, C. E. (1997) · Drugs & Aging · doi:10.2165/00002512-199711020-00001 · Cited by 38
Self-citationThe chaperone Clusterin in neurodegeneration−friend or foe?
Yuste‐Checa, P., Bracher, A., & Hartl, F. U. (2022) · BioEssays · doi:10.1002/bies.202100287 · Cited by 37
Laminin blocks the assembly of wild-type Aβ and the Dutch variant peptide into Alzheimer's fibrils
Bronfman, F. C., Alvarez, A. R., Morgan, C., & Inestrosa, N. C. (1998) · Amyloid · doi:10.3109/13506129809007285 · Cited by 37
Costantini, C., Bianca, V. D., Formaggio, E., Chiamulera, C., Montresor, A., & Rossi, F. (2005) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.09.004 · Cited by 36
Zloković, B. V. (1997) · Neurobiology of Disease · doi:10.1006/nbdi.1997.0134 · Cited by 36
Metadata
- Authors
- Oda, T., Wals, P., Osterburg, H. H., Johnson, S. A., Pasinetti, G. M., Morgan, T. E., Rozovsky, I., Stine, W. B., Snyder, S. W., Holzman, T. F., Krafft, G. A., & Finch, C. E.
- Affiliations
- Northwestern University (US)
- Venue
- Experimental Neurology
- Publisher
- Elsevier BV
- Published
- 1995-11
- Volume
- 136
- Issue
- 1
- Pages
- 22-31
- ISSN
- 0014-4886 (ISSN-L)
- OpenAlex
- W1584774790
- Cited by
- 352
- References
- 0
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 5 · 2023: 7 · 2022: 10 · 2021: 8 · 2020: 9 · 2019: 9 · 2018: 7 · 2017: 9 · 2016: 10 · 2015: 10 · 2014: 10 · 2013: 12 · 2012: 17
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Experimental Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r35ag007909-03)
- National Institute on Aging (AG-1048, AG7909)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Clusterin in disease pathology
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- clusterin, amyloid-beta 42, amyloid fibril formation, Alzheimer's disease, oxidative stress, neurotoxicity, amyloid plaques, diffuse plaques, PC12 cells, MTT assay
- MeSH terms
- Alzheimer Disease, Animals, Complement Inactivator Proteins, Dose-Response Relationship, Drug, Glycoproteins, Humans, Immunohistochemistry, Radioligand Assay, Sucrose, Amyloid beta-Protein Precursor, PC12 Cells, Oxidative Stress, Molecular Chaperones, Clusterin, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
